Keywords : Pharmaceutical
Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends Summary GlobalData’s Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends report analyzes 20 strategic deals struck by leading and promising biotech companies. The terms and strategic drivers of these deals are analyzed based on acquisition costs, strategic fit, potential revenues, competitive advantage as well as other measures to ...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends
Summary
GlobalData’s Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends report analyzes 20 strategic deals struck by leading and promising biotech companies. The terms and strategic drivers of these deals are analyzed based on acquisition costs, strategic fit, potential revenues, competitive advantage as well as other measures to illustrate the strategies different companies are currently using to gain market share, increase shareholder value and bring innovative and life-saving products to the booming global pharmaceuticals market. This report is an essential source of information and analysis on global strategic deals involving the top players in the global pharmaceuticals market.
Scope
- The report provides full details of 20 significant deals from Q3 2011 to Q3 2012 involving promising biotech companies including deal terms and payment structure. The report provides analysis of the key drivers, trends, and strategies behind deals undertaken by biotech companies across important geographic regions including the US, EU, Asia-Pacific, Brazil, Russia, India, China, and other emerging markets. The report covers the six major therapy areas of cardiovascular disease, central nervous system (CNS), diabetes and metabolic, immunology, oncology, and respiratory. The report contains expert insights on the corporate strategies of emerging biotech companies seeking competitive advantage in the pharmaceuticals marketplace.
Reasons to buy
- Analyze and emulate the strategies that promising biotech companies are using to gain market share in the increasingly competitive global pharmaceuticals market.
- Understand the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships.
- Organize your sales and marketing efforts by identifying the business regions and segments to maximize opportunities for consolidation, investment and strategic partnerships.
Pharmaceutical Industry in the United States
Table of Contents
1 Table of CContents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.1.1 Key Questions Answered 9
2.1.2 Key Benefits 10
2.2 Upcoming Related Reports 10
2.3 Recently published reports: 10
3 Historical Dealmaking Trends 11
3.1 Overview 11
3.2 Leading Deal Drivers 11
3.2.1 The Patent Cliff 11
3.2.2 Lack of R&D Innovation 14
3.2.3 Strategic Shift to Emerging Markets 15
3.3 Overall Deals in Review 15
3.3.1 Review by Deal Type 15
3.3.2 Review by Therapy Area 18
3.4 Biotech Deals in Review 19
4 Mergers and Acquisitions 20
4.1 Overview 20
4.2 Gilead Completes $11.1 Billion Acquisition of Pharmasset 22
4.2.1 Deal Description 22
4.2.2 Deal Analysis 23
4.3 GSK Acquires HGS in $3.6 Billion Deal 24
4.3.1 Deal Description 24
4.3.2 Deal Analysis 24
4.4 Valeant Pharmaceuticals Agrees $2.6 Billion Cash Deal for Medicis Acquisition 27
4.4.1 Deal Description 27
4.4.2 Deal Analysis 27
4.5 Amgen Acquires Micromet in $1.1 Billion Deal 29
4.5.1 Deal Description 29
4.5.2 Deal Analysis 29
4.6 Alexion Completes Acquisition of Enobia Pharma in $1.1 Billion Deal 31
4.6.1 Deal Description 31
4.6.2 Deal Analysis 31
4.7 Alkermes Acquires EDT from Elan in $1 Billion Deal 33
4.7.1 Deal Description 33
4.7.2 Deal Analysis 33
4.8 Celgene Acquires Avila Therapeutics in $947.0m Deal 35
4.8.1 Deal Description 35
4.8.2 Deal Analysis 35
4.9 Jazz Pharmaceuticals Completes $678.4m Acquisition of EUSA Pharma 37
4.9.1 Deal Description 37
4.9.2 Deal Analysis 37
4.10 Jazz Pharmaceuticals Completes $576.5m Merger with Azur Pharma 39
4.10.1 Deal Description 39
4.10.2 Deal Analysis 39
4.11 Biogen Idec Closes $562.5m Deal for the Acquisition of Stromedix 42
4.11.1 Deal Description 42
4.11.2 Deal Analysis 42
5 Licensing Deals 44
5.1 Overview 44
5.2 Acorda Signs Marketing License Agreement with Watson Pharma 45
5.2.1 Deal Description 45
5.2.2 Deal Analysis 45
5.3 Baxter Enters Potential $565.0m Deal with Onconova Therapeutics 46
5.3.1 Deal Description 46
5.3.2 Deal Analysis 47
5.4 Exelixis and Merck Involved in “PI3K-?” Licensing Deal 48
5.4.1 Deal Description 48
5.4.2 Deal Analysis 48
5.5 Momenta Enters into Follow-On Biologics Licensing Agreement with Baxter 50
5.5.1 Deal Description 50
5.5.2 Deal Analysis 50
5.6 Nektar and Roche Involved in Manufacturing License Deal 52
5.6.1 Deal Description 52
5.6.2 Deal Analysis 52
6 Collaborations/Partnerships 54
6.1 Overview 54
6.2 Ablynx Extends Nanobody Deal with Boehringer Ingelheim 55
6.2.1 Deal Description 55
6.2.2 Deal Analysis 56
6.3 Novartis Pens Partnership with the University of Pennsylvania 57
6.3.1 Deal Description 57
6.3.2 Deal Analysis 57
6.4 Ironwood Enters into Collaboration Agreement with Bionomics 59
6.4.1 Deal Description 59
6.4.2 Deal Analysis 59
6.5 J&J’s Janssen Biotech Unit Inks Collaboration Deal with Genmab 60
6.5.1 Deal Description 60
6.5.2 Deal Analysis 61
6.6 Pfizer and Mylan Pharmaceuticals Enter into Generics Manufacturing Partnership 62
6.6.1 Deal Description 62
6.6.2 Deal Analysis 62
7 Future Outlook 65
7.1 Overview 65
7.2 Dealmaking Trends 65
7.2.1 Biotech companies, like Big Pharma, will pursue deals to increase their global presence 65
7.2.2 “Small Biotech” will continue to engage in M&A in attempts to make the leap to “Big Biotech” 66
7.2.3 Biotech deal-making will remain a source of IP for Big Pharma 66
8 Appendix 68
8.1 Bibliography 68
8.2 Abbreviations 70
8.3 Research Methodology 72
8.3.1 Coverage 72
8.3.2 Secondary Research 72
8.3.3 Expert Panel Validation 73
8.4 About the Authors 73
8.4.1 Analyst 73
8.4.2 Global Head of Healthcare Research and Consulting 73
8.5 About the Industry Dynamics Team 74
8.6 GlobalData 74
8.7 Contact Us 75
8.8 Disclosure Information 75
8.9 Disclaimer 75
List of Tables
Table 1: Recent and Upcoming US Patent Expirations 12
Table 2: M&A Deals, 3Q11-3Q12 20
Table 3: Gilead’s Acquisition of Pharmasset 24
Table 4: GSK’s Acquisition of HGS 26
Table 5: Valeant Pharmaceutical’s Acquisition of Medicis 29
Table 6: Amgen’s Acquisition of Micromet 30
Table 7: Alexion’s Acquisition of Enobia Pharma 32
Table 8: Alkermes’ Acquisition of EDT from Elan 34
Table 9: Celgene’s Acquisition of Avila Therapeutics 36
Table 10: Jazz Pharmaceuticals’ Acquisition of EUSA Pharma 38
Table 11: Jazz Pharmaceuticals’ Merger with Azur Pharma 42
Table 12: Biogen’s Acquisition of Stromedix 43
Table 13: Acorda’s Licensing Agreement with Watson Pharma 46
Table 14: Acorda’s Licensing Agreement with Watson Pharma 48
Table 15: Exelixis’ Licensing Agreement with Merck 50
Table 16: Momenta’s Licensing Agreement with Baxter 51
Table 17: Nektar’s Licensing Agreement with Roche 53
Table 18: Ablynx’s Collaboration with BI 57
Table 19: Novartis’ Collaboration with the University of Pennsylvania 58
Table 20: Ironwood’s Collaboration with Bionomics 60
Table 21: Janssen’s Collaboration with Genmab 62
Table 22: Pfizer’s Collaboration with the Mylan Pharmaceuticals 64
List of Figures
Figure 1: FDA Approvals of NDAs and BLAs, FY2005-FY2011 14
Figure 2: Deal Analysis - Total Number of Deals and Deal Values ($m), 3Q07-2Q12 16
Figure 3: Deal Analysis - Deals Distribution, 3Q07-2Q12 17
Figure 4: Top 10 Therapeutic Areas by number and Value of Deals, 3Q11-2Q12 18
Figure 5: Biotech Deals Breakdown by Type, Q3 2011-Q3 2012 19
Figure 6: M&A Spending, Q3 2011-Q3 2012 ($m) 22
Figure 7: Xyrem Sales as Percentage of Jazz Pharmaceuticals’ Annual Revenues, 2005-2011 ($m) 40
Figure 8: Licensing Deals1, Q3 2011-Q3 2012 44
Figure 9: Breakdown of Collaboration deals, Q3 2011-Q3 2012 ($m) 55
Figure 10: Pfizer:Emerging Markets Revenues as a Percentage of Annual Revenues, 2006-2011 63
